GRI Bio, Inc. (GRI)
NASDAQ: GRI · Real-Time Price · USD
1.880
-0.040 (-2.08%)
Aug 31, 2026, 2:55 PM EDT - Market open
GRI Bio Employees
GRI Bio had 4 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,414,750
Market Cap
4.11M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - | 3 | 1 |
| Dec 31, 2024 | 4 | 0 | - | 3 | 1 |
| Dec 31, 2023 | 4 | 3 | 300.00% | 4 | 0 |
| Dec 31, 2022 | 1 | - | - | 1 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 47 |
| PMGC Holdings | 34 |
| Aptevo Therapeutics | 33 |
| VivoSim Labs | 15 |
| Revelation Biosciences | 9 |
| Mustang Bio | 4 |
| Addex Therapeutics | 3 |
| Silo Pharma | 3 |
GRI News
- 4 days ago - GRI Bio Featured in "Why Now" On-Demand Video Webcast - GlobeNewsWire
- 7 days ago - GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026 - GlobeNewsWire
- 11 days ago - Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks - New York Post
- 17 days ago - GRI Bio Quarterly report: Q2 2026 - Filings
- 2 months ago - GRI Bio announces U.S. FDA granted ODD to GRI-0621 - TheFly
- 2 months ago - GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 2 months ago - GRI Bio granted FDA orphan designation for tazarotene - TheFly
- 3 months ago - GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - GlobeNewsWire